PROCEPT BioRobotics (PRCT) Faces Lawsuit Scrutiny After Revenue Claims So Is It A Buying Opportunity
Recent securities class action filings against PROCEPT BioRobotics (PRCT) accuse the company of misleading investors on handpiece sales, undisclosed discount programs, and inflated revenue. The allegations are raising fresh questions around its reported growth, guidance cuts, and stock volatility.
See our latest analysis for PROCEPT BioRobotics.
The recent wave of lawsuits helps explain why PROCEPT BioRobotics has had a weak year to date, with the stock showing a 30 day share price return of 22.49% but a 1 year total shareholder return that declined 47.42%.
If you are reassessing PROCEPT BioRobotics after this legal overhang, it can help to compare it with other growth focused medical technology names by scanning 41 healthcare AI stocks
After a sharp rebound over the past month but a steep 1 year decline, PROCEPT BioRobotics now forces a choice. Is this a reasonable entry point in a legally clouded story, or is patience until valuations reset further the safer path?
Most Popular Narrative: 14.2% Undervalued
According to one of the most followed narratives on PROCEPT BioRobotics, the fair value of $25.26 sits above the last close of $21.68. That gap is driving a very different story to what the recent lawsuits and share price swings might suggest.
I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call.
The narrative from Betsareoff leans heavily on projected revenue expansion, a step up in profit margins and a future earnings multiple more often associated with mature, high quality healthcare stocks. Curious what assumptions have to line up for that $25.26 fair value to hold up against today’s legal and sentiment headwinds?
Result: Fair Value of $25.26 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, risks around the securities lawsuits and any further reset to reported revenue could quickly challenge the PROCEPT BioRobotics undervaluation story.
Find out about the key risks to this PROCEPT BioRobotics narrative.
Another View on PROCEPT BioRobotics Valuation
While the user narrative sees PROCEPT BioRobotics as undervalued based on a $25.26 fair value, the SWS DCF model points the other way. At a last close of $21.68, the stock is trading above an estimated future cash flow value of $17.08, which implies it may be overvalued instead. How comfortable are you if the cash flow assumptions prove too optimistic?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PROCEPT BioRobotics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment clearly split on PROCEPT BioRobotics, it makes sense to act promptly, review the underlying data, and form a personal view using the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond PROCEPT BioRobotics?
If PROCEPT BioRobotics has you rethinking your portfolio mix, it is worth scanning other options that match different risk, income, and quality profiles.
- Target dependable income by checking stocks that feature resilient payouts and balance sheets through the 12 dividend fortresses.
- Hunt for potential value opportunities by reviewing companies that appear attractively priced on core fundamentals via the 48 high quality undervalued stocks.
- Prioritise resilience by focusing on companies that carry lower overall risk scores using the 78 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com